Caricamento...
Class effects of SGLT2 inhibitors on cardiorenal outcomes
BACKGROUND: To summarize the four recent sodium-glucose cotransporter 2 inhibitor (SGLT2i) trials: Dapagliflozin Effect on CardiovascuLAR Events (DECLARE-TIMI 58), CANagliflozin CardioVascular Assessment Study (CANVAS) Program, Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mell...
Salvato in:
| Pubblicato in: | Cardiovasc Diabetol |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6683461/ https://ncbi.nlm.nih.gov/pubmed/31382965 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-019-0903-4 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|